Genotyping Market Report By Insights, Size, and Growth - 2031

The genotyping sector is projected to expand significantly, starting from a valuation of US$ 30.44 billion in 2023 and anticipated to reach US$ 154.35 billion by 2031. This growth trajectory indicates a compound annual growth rate (CAGR) of 22.5% from 2023 to 2031. Key factors driving the expansion of the genotyping market include its application in diagnosing genetic and rare diseases, advancements in technology, and increased research and development investments within the biotechnology and pharmaceutical sectors. Nevertheless, challenges such as the high costs associated with equipment and a shortage of skilled professionals may hinder market progress. Additionally, the rising trend of personalized medicine is expected to introduce new dynamics in the genotyping market in the years ahead.

Genotyping represents a promising frontier in the pharmaceutical landscape, providing innovative strategies for addressing various diseases and health conditions. The continuous growth of the genotyping market is largely attributed to substantial investments by pharmaceutical and biotechnology firms aimed at enhancing their production capabilities. The escalating incidence of chronic diseases necessitates the availability of advanced diagnostic tools and therapeutic drugs, thereby propelling the global genotyping market forward. Furthermore, the increasing demand for innovative therapies and the rise in clinical trials are likely to further stimulate market growth. However, the regulatory approval process for biosimilars remains a significant barrier to the expansion of the genotyping market.

In 2023, North America held a substantial share of the global genotyping market. This region's genotyping market is divided into the United States, Canada, and Mexico. Factors such as the growing adoption of advanced technological solutions and heightened research and development activities are contributing positively to the market in North America. Additionally, government initiatives like the "All of Us Research Program," various genomic community projects, and heightened awareness regarding genotyping services are pivotal in driving market growth across this region.

The "All of Us Research Program," spearheaded by the National Institutes of Health (NIH), has allocated US$ 28.6 million to establish three genome centers throughout the United States. This initiative aims to expedite discoveries in precision medicine through the provision of genotyping services across various institutions in the country. Similarly, the "My Life, Our Future" project focuses on genotyping hemophilia patients and creating a biorepository for future research. Moreover, the rapid increase in healthcare spending reflects a growing availability of new diagnostic tools for genetic disorders and cancer. The thriving pharmaceutical and biopharmaceutical sectors create a favorable environment for the genotyping market in the United States, where numerous market players have secured patents for their innovations.

Both governmental and private agricultural organizations are increasingly prioritizing advancements in crop genomics to enhance crop traits. The Agricultural Genome to Phenome Initiative (AG2PI) from the National Institute of Food and Agriculture emphasizes collaborative efforts to cultivate a community of researchers focused on both crop and animal genetics. This initiative aims to deepen understanding of how varying weather conditions, environments, and production systems influence genetic diversity in crops and livestock. Consequently, the growing number of initiatives aimed at studying the genetic composition of crops for improved yield and quality is expected to benefit the genotyping market in the United States in the future.

Expanding Applications to Create Future Market Opportunities

Genotyping has a wide range of potential applications in diagnostic research, pharmacogenomics, and agricultural biotechnology. This technique is also applicable in various plant breeding, forensic, and environmental testing scenarios. Pharmaceutical companies are leveraging the availability of polygenic risk scores, extensive genetic databases linked to patient health records, and sequencing data from clinical trial participants. The Industry Pharmacogenomics Working Group (I-PWG), which consists of pharmaceutical companies, is actively engaged in pharmacogenomic research. This group includes 26 member companies that conduct numerous clinical trials each year, collecting DNA samples from participants as part of their protocols. With a focus on clinical pharmacogenomics, the I-PWG aims to create opportunities for pharmaceutical companies in the near future. Besides its prevalent use in oncology research, genotyping is also utilized in pharmacogenomic studies across non-oncology therapeutic areas, including rare diseases, immunology, and cardiology. Comprehensive studies involving next-generation sequencing (NGS) of clinical trial samples enable detailed genomic evaluations of participants, uncovering both common and rare genetic variations. Pharmacogenomics encompasses the study of polymorphic differences that influence drug effects, responses, and disease susceptibility, as well as genotype-phenotype relationships.

Genotyping-by-sequencing (GBS) is an innovative method for identifying and genotyping single nucleotide polymorphisms (SNPs) in both crop and human genomes using NGS techniques. GBS facilitates the sequencing of multiple samples by integrating molecular markers, thereby enhancing NGS applications in large crop genome sequencing projects, such as those involving maize and wheat. The high-throughput SNPs identified through GBS are extensively utilized in genetic diversity assessments, genome-wide association studies (GWAS), quantitative trait locus (QTL) mapping, and genome prediction (GP) across various plant species. NGS technology has revolutionized modern biology by providing high throughput at reduced costs. With significant advancements enabled by NGS technologies, whole-genome sequencing offers ultra-high-throughput sequences that transform plant genotyping and breeding practices. Techniques such as sequencing by synthesis (SBS) and multiplexing significantly improve sequencing efficiency.

Thus, the increasing adoption of genotyping across diverse research fields is expected to drive demand for these techniques, creating substantial opportunities within the market.

Genotyping Market: Competitive Landscape and Key Developments

Key players in the genotyping market include F. Hoffmann-La Roche Ltd., Integrated DNA Technologies, Inc. (Danaher), Qiagen, Merck KGaA, Eurofins Genomics, Thermo Fisher Scientific Inc., BioTek Instruments, Inc., Xcelris Genomics, Trimgen Corporation, and Illumina, Inc.

The report on the genotyping market references primary and secondary sources, including the US Food and Drug Administration, the Centers for Disease Control and Prevention (CDC), and the Organisation for Economic Co-operation and Development.